2010 Leads Physicians 
World of DTC Marketing
MARCH 23, 2022
85% of accelerated approvals from 2010 to 2020 were for oncology indications. Patients trust their doctors, so the accelerated approval process must be modified to increase their trust with physicians and explain to patients precisely what accelerated drug approval means. Of course not.
World of DTC Marketing
NOVEMBER 3, 2020
Cardiovascular disease deaths in the US have increased by nearly 17% since 2010, and are among the reasons that life expectancy in the U.S. has also seen reversals in health improvements since 2010, partly due to increasing rates of obesity, high blood pressure, and high blood sugar. . is lower than in other high-income countries.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JUNE 6, 2022
Diabetes can lead to serious health complications like heart disease and stroke, so it’s important to take steps to avoid developing the disease if possible. According to an AARP study, in 2010 there were 7 potential caregivers for every person over 80. —and a silent killer. It doesn’t have to be this way.
Pharmaceutical Technology
MAY 15, 2023
Innovation S-curve for the pharmaceutical industry Periodontitis drugs is a notable innovation area in the pharmaceutical industry Periodontal diseases, which may lead to the damage of teeth or bone, are caused by infections and inflammation of the gums and bone that surround and support the teeth.
PM360
NOVEMBER 29, 2022
1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. At the same time, MSLs are being asked to help inform brand strategy with their learnings from talking to leading healthcare professionals. If you apply the right AI engines, you will get increasingly better insights.
Pharmaceutical Technology
MARCH 24, 2023
Until 2010, no regulatory approval pathway for biosimilars existed in the US and the first biosimilar was only approved in the US in 2015. Many experts have concerns that only a few Humira biosimilars will have access to the US market, while the rest will not be listed, thereby leading to lower savings than expected.
Pharmaceutical Technology
OCTOBER 5, 2008
“The Japanese government is encouraging physicians to use more generic drugs,” Sato explains, adding that this is in part due to the ageing population and increased price of effective healthcare. Like in many other sectors, China and India are the ones labelled as those which will lead the expansion.
Expert insights. Personalized for you.
200 
Let's personalize your content